Fig. 1

The diagrammatic schema of miniHCVD-inotuzumab ozogamicin-blinatumomab regimen. This was adapted from Jabbour et al. (2018) and Short et al. (2018). Detailed dosages and schedules are summarized in Table 4. miniHCVD low-dose hyper-fractionated cyclophosphamide, vincristine, dexamethasone. MTX methotrexate. INO inotuzumab ozogamicin; POMP prednisone, vincristine, methotrexate, mercaptopurine; D day